SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

SAN

99.62

-0.56%↓

EI

248.8

-7.03%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

Search

Innate Pharma SA

Închisă

1.8 -1.85

Rezumat

Modificarea prețului

24h

Curent

Minim

1.7

Maxim

1.856

Indicatori cheie

By Trading Economics

Venit

-25M

Vânzări

12M

Marjă de profit

-200.599

Angajați

181

EBITDA

-26M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+137.75% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

159M

Deschiderea anterioară

3.65

Închiderea anterioară

1.8

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Innate Pharma SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 apr. 2025, 23:55 UTC

Acțiuni populare

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr. 2025, 22:50 UTC

Principalele dinamici ale pieței

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr. 2025, 21:08 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr. 2025, 21:00 UTC

Câștiguri

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr. 2025, 23:56 UTC

Market Talk

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:44 UTC

Market Talk

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr. 2025, 23:44 UTC

Top știri

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr. 2025, 23:32 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 23:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 23:32 UTC

Market Talk

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

2 apr. 2025, 23:12 UTC

Market Talk

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr. 2025, 23:10 UTC

Market Talk

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr. 2025, 23:09 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:57 UTC

Market Talk

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr. 2025, 22:56 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 22:56 UTC

Market Talk

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr. 2025, 22:43 UTC

Top știri
Achiziții, Fuziuni, Preluări

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr. 2025, 22:12 UTC

Market Talk

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr. 2025, 21:48 UTC

Top știri

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr. 2025, 21:41 UTC

Market Talk

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

2 apr. 2025, 21:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2 apr. 2025, 21:17 UTC

Market Talk

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr. 2025, 21:04 UTC

Top știri

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr. 2025, 21:03 UTC

Market Talk

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr. 2025, 20:53 UTC

Câștiguri

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr. 2025, 20:52 UTC

Câștiguri

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparație

Modificare preț

Innate Pharma SA Așteptări

Obiectiv de preț

By TipRanks

137.75% sus

Prognoză pe 12 luni

Medie 4.398 EUR  137.75%

Maxim 5.7 EUR

Minim 3.1 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruInnate Pharma SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.85 / 1.88Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.